Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 35367007

Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2022 Apr 30
First author
Luke JJ

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2022 Jun;19(6):359. doi: 10.1038/s41571-022-00638-w.
    note
    Source null
    related pmid
    35440772
    relationship
    Comment in
  2. citation
    Lancet. 2022 Aug 20;400(10352):559. doi: 10.1016/S0140-6736(22)01388-5.
    note
    Source null
    related pmid
    35988562
    relationship
    Comment in

Authors and identifiers

  1. name
    Luke JJ
    type
    Author
  2. name
    Rutkowski P
    type
    Author
  3. name
    Queirolo P
    type
    Author
  4. name
    Del Vecchio M
    type
    Author
  5. name
    Mackiewicz J
    type
    Author
  6. name
    Chiarion-Sileni V
    type
    Author
  7. name
    de la Cruz Merino L
    type
    Author
  8. name
    Khattak MA
    type
    Author
  9. name
    Schadendorf D
    type
    Author
  10. name
    Long GV
    type
    Author
  11. name
    Ascierto PA
    type
    Author
  12. name
    Mandala M
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Luke JJ
    type
    Author
  2. name
    Rutkowski P
    type
    Author
  3. name
    Queirolo P
    type
    Author
  4. name
    Del Vecchio M
    type
    Author
  5. name
    Mackiewicz J
    type
    Author
  6. name
    Chiarion-Sileni V
    type
    Author
  7. name
    de la Cruz Merino L
    type
    Author
  8. name
    Khattak MA
    type
    Author
  9. name
    Schadendorf D
    type
    Author
  10. name
    Long GV
    type
    Author
  11. name
    Ascierto PA
    type
    Author
  12. name
    Mandala M
    type
    Author
bibliography ids
  1. nci-bib-1a8bb14635c62d9f494583ec
book metadata
content sha256
7cf0d6f9d0345b70b64a14401d9ec9f0983b22e8438cd4966e73eec4be31a17d
document type
citation
dois
  1. 10.1016/S0140-6736(22)00562-1
electronic publication date
display
2022 Apr 1
precision
day
year
2022
evidence scope
bibliographic_metadata_only
id
pubmed:35367007
immutable id
pubmed:35367007@7cf0d6f9d0345b70b64a14401d9ec9f0983b22e8438cd4966e73eec4be31a17d
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
10336
name
Lancet (London, England)
nlm unique id
2985213R
pages
1718-1729
volume
399
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2022 Jun;19(6):359. doi: 10.1038/s41571-022-00638-w.
    note
    Source null
    related pmid
    35440772
    relationship
    Comment in
  2. citation
    Lancet. 2022 Aug 20;400(10352):559. doi: 10.1016/S0140-6736(22)01388-5.
    note
    Source null
    related pmid
    35988562
    relationship
    Comment in
outcomes validated
false
pmid
35367007
provenance
batch id
3f4d1914d2afe41e9e70
provider
NCBI PubMed ESummary
record sha256
b31d227ffa4397ee13afa80bfe11c863204c399a6c3239e777accf5c76f3d12b
response sha256
0ceeb248a527e54c6f72dd28d20f7abec08a973fe2e10de00bede4895add09e7
retrieved at
2026-09-09T23:48:06.522634+00:00
publication date
display
2022 Apr 30
precision
day
year
2022
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/35367007/
title
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.

Preserved source evidence · Not medical advice